Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 2Terminated 1Suspended 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Tumor-Agnostic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 8Neoplasms 4Neoplasm Metastasis 4Endometrial Neoplasms 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Prostatic Diseases 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Male Urogenital Diseases 1Leukemia, Myeloid, Acute 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Genital Diseases, Male 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Advanced Cancer 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Neoplasms × gedatolisib × Clear all
NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Suspended
75 enrolled
GastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

NCT01920061 2022-09-13

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Pfizer

Phase 1 Completed
110 enrolled 80 charts
Breast

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT01420081 2019-01-08

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Pfizer

Phase 2 Terminated
67 enrolled 37 charts
Gynecologic

Neoplasm Metastasis, Neoplasms, Recurrence, Uterine Neoplasms, Endometrial Neoplasms

NCT00940498 2018-11-02

B2151001

Pfizer

Phase 1 Completed
78 enrolled 26 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡